PTC Celebrates 10 Years of Impact in Europe

It has been 10 years since PTC entered the European market with a mission to improve the lives of people living with rare diseases.  In the past decade, we have pioneered transformative progress and created possibilities for the rare disease community across Europe.

PTC was founded with the mission to leverage its novel drug discovery platforms to deliver transformative medicines to treat multiple rare genetic disorders. In 2014, we brought that same commitment to patients in Europe. Over the last decade we’ve proudly served the rare disease community with pioneering medicines, initiatives that change the trajectory of rare diseases and unwavering commitment to improve the quality of life of patients and families.

As we celebrate our 10-year anniversary in Europe, our impact can be measured by the possibilities we have created for patients and rare disease community, healthcare partners, industry and society.   

Pioneering Medicines

Roger Johannson

“Over the past decade, we have delivered multiple transformative therapies to patients in Europe that have improved their lives. First-of-kind novel treatment modalities for Duchenne Muscular Dystrophy (DMD), Aromatic L-amino acid decarboxylase (AADC) deficiency have not only transformed lives but also reduced the burden on patients, families and healthcare systems. We have worked tirelessly to provide access to our medicines for patients living with rare diseases across all markets. This remains our focus in the future. As PTC continues to develop new therapies across new therapeutics areas, our priority will be to deliver them to patients across Europe,” says Roger Johansson, Senior Vice President responsible for PTC Western Europe.

Better Health Outcomes

“For a small company, PTC displayed a ton of grit in its first 10 years in Europe. We never shied away from taking chances and making strategic investments – all for the sake of our patients. Over the past decade, we’ve expanded across and beyond Europe; our innovative therapies currently benefit patients in over 35 countries across the CEMEA^* region and that number continues to grow. Our innovative approaches to developing, manufacturing and commercializing first-/best-in-class therapies have blazed a trail for patients to access the medicines they need.  Our programs to improve stakeholder education, diagnostics, healthcare capabilities and bolster community resources, have contributed to better health outcomes and standards of care for our patients. Our goal is to continue pushing ahead with this same determination and grit into the future,” says Jesse Sibarium, Senior Vice President responsible for CEMEA.

Community Development

“Working closely with patient organizations, we have supported impactful new opportunities in communities across the region and have made impactful progress over the last decade.  Through our STRIVE Awards program alone we have supported 15 organizations across Europe to implement new and exciting initiatives that address unmet needs. Our educational programs and resources enhanced knowledge and care while initiatives such as sponsorship of the Powerchair Football and Powerchair Hockey World Cup supported opportunities for social inclusion and participation in sport.  Ongoing collaborations with +100 patient groups have accelerated advocacy and patient organizational development. We remain committed to the rare disease community with the goal to achieve even more in the following decade,” says Sian O’Neill, Senior Director, Patient Engagement covering Europe, Middle East, Africa (EMEA).

Entrepreneurs and innovators

“Our enriched culture of innovation and entrepreneurship has been key to PTC’s success in Europe and globally.  As we have grown from just a few employees in 2014 to a more diverse +180 people workforce in the region now (~1000 globally), we have fostered a mindset of continuous improvement across the entire organization. This has driven new breakthroughs and ventures, novel approaches and solutions in the rare disease space. Through numerous people development initiatives, PTC cultivates future leaders, diverse talent and continues to strengthen its equitable workplace. PTC is at the forefront of innovation, creating pioneering advances in science and supporting progress in the rare disease community,” says Hege Sollie-Zetlmayer, Chief Human Resources Officer.

After a decade of pioneering progress in the industry and community we are proud to celebrate our achievements, including various recognitions we have received:

• Eurordis ‘Company Award for Innovation’ 2023
• INTRAMA ‘Cultural Diversity’ Award 2023
• The LifeScience Industry Ireland ‘Supply Chain Achievement Award’ 2023
• EuropaBio ‘25 Years of Innovation’ company 2021
• Don Clifton ‘Strengths-Based Culture Award” 2021, 2023, 2024
• Le Fonti Italy ‘Excellence in Biopharmaceutical Innovation & Leadership’ 2019-2023
• Prix Galien France ‘‘Innovative Medicine in Rare Disease’ 2016

Follow our channels to learn more about our people and our efforts to transform more lives.